Verition Fund Management
ABBV icon

Verition Fund Management’s AbbVie ABBV Stock Holding History

Verition Fund Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.29M Sell
28,900
-7,700
-21% -$1.71M 0.04% 489
2025
Q4 		$8.36M Sell
36,600
-16,000
-30% -$3.64M 0.03% 552
2025
Q3 		$12.2M Buy
52,600
+9,600
+22% +$1.95M 0.05% 411
2025
Q2 		$7.98M Buy
43,000
+16,300
+61% +$3.03M 0.04% 676
2025
Q1 		$5.59M Sell
26,700
-10,700
-29% -$2.08M 0.03% 762
2024
Q4 		$6.65M Sell
37,400
-28,000
-43% -$5.15M 0.03% 724
2024
Q3 		$12.9M Sell
65,400
-14,800
-18% -$2.76M 0.07% 287
2024
Q2 		$13.8M Buy
80,200
+18,200
+29% +$3.01M 0.08% 235
2024
Q1 		$11.3M Buy
62,000
+38,500
+164% +$6.64M 0.08% 292
2023
Q4 		$3.64M Sell
23,500
-8,100
-26% -$1.18M 0.03% 567
2023
Q3 		$4.71M Buy
31,600
+10,300
+48% +$1.51M 0.05% 461
2023
Q2 		$2.87M Buy
+21,300
New +$3.12M 0.04% 535
2023
Q1 		– Sell
-23,100
Closed -$3.73M – 2118
2022
Q4 		$3.73M Sell
23,100
-2,900
-11% -$445K 0.06% 414
2022
Q3 		$3.49M Buy
+26,000
New +$3.73M 0.04% 598
2022
Q2 		– Sell
-30,100
Closed -$4.88M – 2275
2022
Q1 		$4.88M Sell
30,100
-5,200
-15% -$755K 0.06% 400
2021
Q4 		$4.78M Buy
+35,300
New +$4.17M 0.03% 385
2021
Q1 		– Sell
-581,400
Closed -$62.3M – 1512
2020
Q4 		$62.3M Sell
581,400
-102,100
-15% -$9.81M 0.55% 43
2020
Q3 		$59.9M Sell
683,500
-186,700
-21% -$17.6M 1.2% 17
2020
Q2 		$85.4M Buy
870,200
+225,800
+35% +$19.9M 2.81% 5
2020
Q1 		$49.1M Buy
644,400
+166,100
+35% +$14.1M 1.94% 8
2019
Q4 		$41.8M Buy
478,300
+442,100
+1,221% +$36.7M 0.76% 26
2019
Q3 		$2.7M Sell
36,200
-3,800
-10% -$261K 0.07% 178
2019
Q2 		$2.91M Buy
+40,000
New +$3.14M 0.08% 172

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Verition Fund Management's ABBV Position: Q1 2026 in Review

Verition Fund Management reduced its AbbVie (ABBV) stake by 90% in Q1 2026, selling an estimated $7.07M and leaving 3,553 shares worth $773K. The position accounts for 0.01% of the portfolio, ranked #1413.

Verition Fund Management first reported a position in ABBV in Q2 2013 and has held it in 35 quarters since. The position peaked at $16.4M in Q1 2020. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Verition Fund Management held 3,553 shares of AbbVie worth $773K as of Q1 2026.
  • Verition Fund Management sold 31,852 AbbVie shares in Q1 2026, an estimated $7.07M.
  • AbbVie made up 0.01% of Verition Fund Management's portfolio in Q1 2026, its #1413 holding.
  • Verition Fund Management first reported a position in AbbVie in Q2 2013 and has held it in 35 quarters since.
  • Verition Fund Management's AbbVie position peaked at $16.4M in Q1 2020.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.